Alexion Pharmaceuticals, Inc.

• Catalyst Pharmaceuticals Successfully Repositions In Hot Orphan Drug Space

  By Michael Anderson - May 23, 2013 | Tickers: ALXN, BMRN, CPRX, PFE, SNY

  I was surprised to see Catalyst Pharmaceutical Partners, (NASDAQ: CPRX) Inc. break out to the upside following the announcement last November of disappointing results from the latest clinical trial of CPP-109 for cocaine addiction. After forming a solid base around $.50 for the past three months, Catalyst spiked to $1.06 and is now consolidating its' gain.  Technically, Catalyst looks like it is getting ready for another big advance.

  I more »

• Is This Momentum Stock’s Rally Over?

  By Brian Nichols - May 22, 2013 | Tickers: ALXN, REGN

  Regeneron Pharmaceuticals (NASDAQ: REGN) peaked on May 14 with a price of $283.99, and has since pulled back to its current price of $260. The drugmaker has been one of the best-performing stocks of the last few years, trading higher regardless of market trend. After many years of gains, some are wondering whether now's the time to take profits. Here's why I think it's not.

  A more »

• Despite Large Gains, This Stock Is Still a Buy

  By Brian Nichols - May 20, 2013 | Tickers: ACT, ALXN, WCRX

  Rumors of mergers and takeovers have overshadowed the good fundamental news surrounding Actavis (NYSE: ACT). Actavis is the world’s third largest generic drug maker, and is growing just as fast as any of the high-profile pharmaceutical names. Now, with takeover chatter beginning to fade, investors can turn their focus back towards fundamentals, and the large upside that is still present.

  The Actavis Sweepstakes

  If you’re a new investor more »

• The Market's Got This Biotech All Wrong

  By Brian Nichols - May 3, 2013 | Tickers: ALXN, QCOR

  Many believed that Q1 earnings would be the start of a larger trend higher that reversed the losses seen in shares of Questcor Pharmaceuticals (NASDAQ: QCOR) over the last year, but were those people ever wrong.

  Q1 Earnings

  Questcor Pharmaceuticals is trading with losses of 9% immediately following its Q1 earnings report. For the quarter, Questcor grew 41% and posted revenue of $135 million and an EPS of $0.76 more »

• A Look at Biotechnology’s Hot Name & Its Lack of Value

  By Brian Nichols - April 29, 2013 | Tickers: ALXN, JAZZ

  Shares of Alexion Pharmaceuticals (NASDAQ: ALXN) saw a double-digit move during the final two days of last week. The company had seen consolidation over the last year but now many believe its uptrend will continue. While this is possible, investors must take notice of its valuation, and look throughout the market for better value.

  Alexion Pharmaceuticals & Its Premium Price

  Alexion Pharmaceuticals’ large move higher came after the company announced earnings more »

• Multi-billion Dollar Hedge Fund Bullish on These Stocks

  By Meena Krishnamsetty - April 23, 2013 | Tickers: ALXN, AZO, CMCSA, EMC, LVS

  Note: There were two errors in the original version of this article: (1) Soliris is approved for both aHUS and PNH (Paroxysmal Nocturnal Hemoglobinuria). (2) Alexion holds the patent until 2021 in the US and until 2020 in most European countries. Insider Monkey regrets the errors, and they have been corrected. 

  Viking Global is a multi-billion dollar hedge fund run by Norwegian native Andreas Halvorsen. The fund made an more »

• Orphan Drug Biotechs Do It Best

  By Terry Chrisomalis - April 19, 2013 | Tickers: ALXN, BMRN, VRTX

  There are many biotech stocks to choose from that have long-lasting value. Each one can potentially have huge value, but there is a group of biotech stocks that focus only on orphan drugs. You might ask why you should bother investing in this type of biotech stocks? Because these companies treat rare diseases with limited treatment options. 

  In my opinion, these biotech stocks perform better than their peers, and will more »

• Multi Billion Dollar Hedge Fund Bullish On These Stocks

  By Meena Krishnamsetty - April 18, 2013 | Tickers: ALXN, AZO, CMCSA, EMC, LVS

  Viking Global is a multi billion dollar hedge fund run by Norwegian native Andreas Halvorsen. The fund made an amazing 89% in its first year, and is global equity-focused with a bottom-up strategy, which explains the diverse sectors within its equity portfolio. According to the 4Q 13F, Viking Global added to their already plentiful positions. Let’s see the top five new picks for Andreas Halvorsen and Viking Global, because more »

• Orphan Drug Biotechs Do It Best

  By Terry Chrisomalis - April 16, 2013 | Tickers: ALXN, BMRN, VRTX

  There are many biotech stocks to choose from that have long lasting value. Each one can potentially have huge value, but there is a group of biotech stocks that focus only on orphan drug status. You might ask why invest in these types of biotech stocks? It is quite simple really, these types of companies treat rare diseases with limited treatment options. 

  In my opinion I feel these biotech stocks more »

• How to Play the Immediate Uncertainty of this Promising Biotech Stock

  By Brian Nichols - April 7, 2013 | Tickers: ALXN, BMRN, SRPT

  Sarepta Therapeutics (NASDAQ: SRPT) has been one of the best performing stocks of the last year, and has among the greatest level of promise in the biotechnology industry. However, it faces immediate uncertainty, and because of that uncertainty I am exploring the best way to play the stock.

  A 50/50 Chance is a Gamble

  Sarepta Therapeutics has been volatile over the last few sessions, but saw a 5.17 more »

• 2 Value BioPharmacetuicals for Your Portfolio

  By Mohsin Saeed - February 26, 2013 | Tickers: ALXN, GILD, INCY

  In my recent articles, I have highlighted that investor’s love for the biopharmaceutical industry has ensured huge returns for some stocks. While this attention is good for the industry and investors have made a lot of money, it becomes pretty hard to find good solid value investments. Therefore I have tried to find a couple of good bargains which have still gone unnoticed and offer exciting opportunity for prospective more »

• Biotech: Core and Explore

  By Reuben Brewer - January 22, 2013 | Tickers: ALXN, AMGN, EXEL |

  When it comes to finding new drugs, biotechs are often at the leading edge. While that can lead to huge profits, it also leads to frequent flame outs. With a small number of large biotech firms, investors interested in the area would do well to use a core and explore approach to limit their downside risk.

• Biotech's Next Major Pullback

  By Brian Nichols - December 11, 2012 | Tickers: ALXN, BMRN, PCYC, REGN

  There’s no denying that biotechnology is the ultimate industry of momentum, where companies often trade with multi-year rallies, reaching valuations that can not possibly be explained. In the last six months we have witnessed the fall of Alexion Pharmaceuticals (NASDAQ: ALXN) from its multi-year rally, and in this article I am looking at which companies might be next.  

  Back in October Alexion Pharmaceuticals reached an all-time high of $119 more »

• BioMarin Still Presents Upside Despite Gains

  By Brian Nichols - November 6, 2012 | Tickers: ALXN, BMRN

  BioMarin Pharmaceuticals (NASDAQ: BMRN) is a biotechnology company with very modest sales growth, is not profitable, and trades with a valuation that implies it to be one of the faster growing companies in biotechnology. The company, which sports a price/sales ratio of 9.72, is priced expensively because of its pipeline and its potential. On Monday the company’s stock traded higher by 30% after positive results from its more »

• 5 High P/E Stocks Loved by Hedge Funds

  By Meena Krishnamsetty - October 26, 2012 | Tickers: ALXN, AMZN, FB, V, WFM

  We have identified five stocks that might be scary to some investors, but are loved by hedge funds. These stocks trade at P/E ratios that seem completely ridiculous, especially when compared to their industry averages.

  The following five stocks are trading at ridiculously high price-to-earnings ratios, yet have a huge following of billionaire fund managers that continue to load up. All companies discussed here are expected to grow EPS more »

• New Top Stock Picks from Navellier & Associates

  By Meena Krishnamsetty - October 23, 2012 | Tickers: ALXN, ADS, AAPL, EQIX, IBM

  Louis Navellier founded Navellier & Associates in 1980 and is primarily a growth investor, preferring to invest in growing companies with good fundamentals. He is also the editor of several investing newsletters and wrote The Little Book That Makes You Rich. Earlier this month Navellier filed its 13F with the SEC; this filing reports many of the fund’s long stock positions as of the end of the quarter (the end more »

• Spectacular Growth Prospects

  By Sharmistha Banerjee - September 18, 2012 | Tickers: ALXN, REGN, SPPI

  The biotechnology industry is fuelling mobility and economic growth and it is expected to show a strong upward momentum in the future. Many investors once considered biotech stocks untouchable, but all that is about to change.  

  Spectrum Pharmaceuticals (NASDAQ: SPPI) a small, fast growing company which has achieved almost quadruple its revenue is gradually getting its due recognition in the biotechnology industry. The strengths and opportunities outnumber the weaknesses and more »

• Three Missed ETFs that are Less Visible and Roar

  By Jeff Stouffer - September 4, 2012 | Tickers: ALXN, CZA, CCI, ETE, IWP, MDY, OKS, REGN, VRTX

  One of the most overlooked investment ideas is Mid-Cap stocks. Large-Cap stocks are clearly recognized by being components of the S&P 500 or the Dow Jones Industrial Average. Small-Cap stocks get notoriety from being part of either the Russell 200 or the S&P 600 SmallCap Index. Event thought there is the S&P MidCap 400 Index it seems to not get the same amount of attention, especially by more »

• Bio Buyouts

  By AnnaLisa Kraft - July 28, 2012 | Tickers: ALXN, BMRN, IDIX, REGN, VRTX

  For biotech investors a positive phase III clinical trial is like a home run, an FDA approval is like a game winning grand slam but a buyout is like winning the World Series with fireworks, rainbows and unicorns. (OK, not unicorns). A buyout is what every biotech investor dreams of and over this last year there have been some monster buyouts.

  Biotech is usually about binary events like FDA approvals more »

• Potential in Alexion Pharmaceuticals

  By George Liu - May 30, 2012 | Tickers: ALXN

  The Overview

  On May 24, 2012, Alexion Pharmaceuticals (NASDAQ: ALXN) became the latest company to be included in the S&P 500 index, replacing Motorola Mobility (which has been acquired by Google). Upon news of this selection, Alexion's stock gained 5.2%, an increase which follows a long string of successes for the company and its stock. In fact, Alexion Pharmaceuticals has seen its stock price rise 29.3 more »

• Page 1 of 2
• »